The report highlights the company's commitment to sustainable development through the integration of ESG principles into its corporate strategy and operations. Huadong Medicine emphasizes its dedication to research and development, environmental protection, social responsibility, and corporate governance, outlining its goals for each area and the milestones achieved throughout the year. Specific achievements include the approval of Liraglutide injection, the acquisition of a stake in Nanjing Nongda Animal Pharmaceutical, and a focus on environmental protection initiatives, including reducing its carbon footprint and implementing water conservation measures. The report also details the company's proactive engagement with stakeholders through various communication channels.
Go back to company
Huadong Medicine Co Ltd 2023 ESG Report
Issuing Company Huadong Medicine Co., Ltd.
Report Type Sustainability Report
Report Language EN
Report Filesize 22.41 MB
No. of Pages 51 pages
Reporting periodJanuary 1, 2023-December 31, 2023
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; CASS-ESG 5.0; Guide for Business Action on the SDGs; ot...
Materiality Assessmenttrue